Klinik protokol Az ərbaycan Respublikas

Yüklə 0,77 Mb.

səhifə	65/65
tarix	28.12.2021
ölçüsü	0,77 Mb.
	#10383

1 ... 57 58 59 60 61 62 63 64 65

Ədəbiyyat:

1. Arterial hipertenziyanın diaqnostika və müalicəsi üzrə klinik protokol.

Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2009. - 64 səh.

2. Kəskin koronar sindromun diaqnostika və müalicəsi üzrə klinik

protokol. Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2012.

- 60 səh.

3. Sabit stenokardiyanın diaqnostika və müalicəsi üzrə klinik protokol.

Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2009 - 48 səh.

4. Şəkərli diabet (tip 2) xəstəliyinin diaqnostika və müalicəsi üzrə klinik

protokol. Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2009.

- 36 səh.

5. Tütünçəkmədən imtina etmə üzrə klinik protokol. Azərbaycan

Respublikasının Səhiyyə Nazirliyi. - Bakı, 2012. - 44 səh.

6. Ürək çatışmazlığının diaqnostika və müalicəsi üzrə klinik protokol.

Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2010. - 64 səh.

7. Albert M.A., Glynn R.J., Buring J., Ridker P.M. Impact of traditional

and novel risk factors on the relationship between socioeconomic status

and incident cardiovascular events. Circulation - 2006. 114:2619-2626.

8. Amarenco P, LabreucheJ. Lipid management in the prevention of

stroke: review and updated meta-analysis of statins for stroke

prevention. Lancet Neurol. - 2009. 8:453-463.

9. American Association of Cardiovascular & Pulmonary Rehabilitation.

Guidelines for Cardiac Rehabilitation and Secondary Prevention

Programs. Champaign, IL: Human Kinetics. - 2004.

10. American College of Sports Medicine. ACSM’s Guidelines for

Exercise Testing and Prescription. 8th ed. Baltimore, MD: Lippincott,

Williams and Wilkins. - 2009.

11. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of

randomised trials of antiplatelet therapy for prevention of death,

myocardial infarction, and stroke in high risk patients. BMJ. - 2002. -

324:71-86.

12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at

risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Lancet. - 1996. - 348:1329-1339.

13. Astrup A., Dyerberg J., Elwood P., Hermansen K., Hu F.B., Jakobsen

M.U., et al. The role of reducing intakes of saturated fat in the

prevention of cardiovascular disease: where does the evidence stand in

2010? Am J Clin Nutr. - 2011. 93:684-688.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

14. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering

for peripheral arterial disease of the lower limb. Cochrane Database

Syst Rev. - 2007. - 4: CD000123.

15. Baigent C, Blackwell L, Emberson J, Collins R, et al. Aspirin in the

primary and secondary prevention of vascular disease: collaborative

meta-analysis of individual participant data from randomised trials.

Lancet. - 2009. - 373:1849-1860.

16. Baigent C, Blackwell L, Emberson J, Holland LE, et al. Efficacy and

safety of more intensive lowering of LDL cholesterol: a meta-analysis

of data from 170,000 participants in 26 randomised trials. Lancet. -

2010. - 376:1670-1681.

17. Balady G.J., Williams M.A., Ades P.A., Bittner V., Comoss P., Foody

J.M., et al. Core components of cardiac rehabilitation/secondary

prevention programs: 2007 update: a scientific statement from the

American Heart Association Exercise, Cardiac Rehabilitation, and

Prevention Committee, the Council on Clinical Cardiology; the

Councils on Cardiovascular Nursing, Epidemiology and Prevention,

and Nutrition, Physical Activity and Metabolism; and the American

Association of Cardiovascular and Pulmonary Rehabilitation.

Circulation. - 2007. - 115:2675-2682.

18. Berger J.S., Jordan C.O., Lloyd-Jones D., Blumenthal R.S. Screening

for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. -

2010. - 55:1169-1177.

19. Billman G.E. Cardiac autonomic neural remodeling and susceptibility

to sudden cardiac death: effect of endurance exercise training. Am J

Physiol Heart Circ Physiol. - 2009. 297:H1171-H1193.

20. Bjarnason-Wehrens B., Grande G., Loewel H., Voller H., Mittag O.

Genderspecific i ssues in cardiac rehabilitation: do women with

ischemic heart 304. // Verschuren W.M., Jacobs D.R., Bloemberg B.P.,

Kromhout D., et al. Serum total cholesterol and long-term coronary

heart disease mortality in different cultures. Twenty-five-year followup

of the seven countries study. JAMA. - 1995. 274:131-136.

21. Blackburn D.F., Lamb D.A., Eurich D.T., Johnson J.A., Wilson T.W., et

al. Atenolol as initial antihypertensive therapy: an observational study

comparing first-line agents. J Hypertens. - 2007. 25:1499-1505.

22. Boffetta P., Straif K. Use of smokeless tobacco and risk of myocardial

infarction and stroke: systematic review with meta-analysis. BMJ. -

2009. 339: b3060.

23. Borjesson M., Urhausen A., Kouidi E., Dugmore D., Sharma S., et al.

Cardiovascular evaluation of middle-aged/senior individuals engaged in

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

leisure-time sport activities: position stand from the sections of exercise

physiology and sports cardiology of the European Association of

Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev

Rehabil. - 2011. 18: 446-458.

24. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, et al. The benefits of statins

in people without established cardiovascular disease but with

cardiovascular risk factors: meta-analysis of randomised controlled

trials. BMJ. - 2009. - 338:b2376.

25. Byington RP, Davis BR, Plehn JF, White HD, et al. Reduction of stroke

events with pravastatin: the Prospective Pravastatin Pooling (PPP)

Project. Circulation. - 2001. - 103:387-392.

26. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for

smoking cessation. Cochrane Database Syst Rev. - 2008. 3: CD006103.

27. Center for Disease Control and Prevention [Electronic resource]: How

Tobacco Smoke Causes Disease: The Biology and Behavioural Basis

for Smoking-attributable Disease. A Report of the Surgeon General. -

2010.

Availabe

at:

http://www.surgeongeneral.gov/library/

tobaccosmoke/index.html (12.02.2014).

28. Chandola T., Britton A., Brunner E., Hemingway H., Malik M., Kumari M.,

Badrick E., Kivimaki M., Marmot M. Work stress and coronary heart

disease: what are the mechanisms? Eur Heart J. - 2008. 29:640-648.

29. Chen ZM, Jiang LX, Chen YP, Xie JX, et al. Addition of clopidogrel to

aspirin in 45,852 patients with acute myocardial infarction: randomised

placebo-controlled trial. Lancet. - 2005. - 366:1607-1621.

30. Chida Y., Steptoe A. The association of anger and hostility with future

coronary heart disease: a meta-analytic review of prospective evidence.

J Am Coll Cardiol. - 2009. 53:936-946.

31. Claesson M., Birgander L.S., Lindahl B., Nasic S., Astrom M., Asplund

K., Burell G. Women’s hearts-stress management for women with

ischemic heart disease:explanatory analyses of a randomized controlled

trial. J Cardiopulm Rehabil. - 2005. 25:93-102.

32. Clark A.M., Hartling L., Vandermeer B., McAlister F.A. Meta-analysis:

secondary prevention programs for patients with coronary artery

disease. Ann Intern Med. - 2005. - 143:659-672.

33. Clarke R., Halsey J., Lewington S., Lonn E., Armitage J., et al. Effects

of lowering homocysteine levels with B vitamins on cardiovascular

disease, cancer, and cause-specific mortality: meta-analysis of 8

randomized trials involving 37 485 individuals. Arch Intern Med. -

2010. 170:1622-1631.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

34. Cohen H.W., Gibson G., Alderman M.H. Excess risk of myocardial

infarction in patients treated with antidepressant medications:

association with use of tricyclic agents. Am J Med. - 2000. 108:2-8.

35. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil

H.A., et al. Primary prevention of cardiovascular disease with

atorvastatin in type 2 diabetes in the Collaborative Atorvastatin

Diabetes Study (CARDS): multicentre randomized placebo-controlled

trial. Lancet. - 2004. 364:685-696.

36. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF Heart

Protection Study of cholesterol-lowering with simvastatin in 5963

people with diabetes: a randomised placebo-controlled trial. Lancet. -

2003. 361:2005-2016.

37. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., et al.

Estimation of ten-year risk of fatal cardiovascular disease in Europe:

the SCORE project. Eur Heart J. - 2003. 24:987-1003.

38. Cooney M.T., Dudina A., De Bacquer D., Wilhelmsen L., Sans S., et

al. HDL cholesterol protects against cardiovascular disease in both

genders, at all ages and at all levels of risk. Atherosclerosis. - 2009.

206:611-616.

39. Cossette S., Frasure-Smith N., Lesperance F. Clinical implications of a

reduction in psychological distress on cardiac prognosis in patients

participating in a psychosocial intervention program. Psychosom Med.

- 2001. 63:257-266.

40. Critchley J., Capewell S. Smoking cessation for the secondary

prevention of coronary heart disease. Cochrane Database Syst Rev. -

2004. 1: CD003041.

41. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., et al.

Prevention of cardiovascular events with an antihypertensive regimen

of amlodipine adding perindopril as required versus atenolol adding

bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac

Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a

multicentre randomized controlled trial. Lancet. - 2005. 366:895-906.

42. Dauchet L., Amouyel P., Hercberg S., Dallongeville J.. Fruit and

vegetable consumption and risk of coronary heart disease: a meta-

analysis of cohort studies. J Nutr. - 2006. 136:2588-2593.

43. De Berardis G., Sacco M, Strippoli G.F., Pellegrini F., Graziano G., et

al. Aspirin for primary prevention of cardiovascular events in people

with diabetes: meta-analysis of randomised controlled trials. BMJ. -

2009. 339: b4531.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

44. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, et al. Earlyintensive

vs a delayed conservative simvastatin strategy in patients with acute

coronary syndromes: phase Z of the A to Z trial. JAMA. - 2004. -

292:1307-1316.

45. Denollet J., Gidron Y., Vrints C.J., Conraads V.M. Anger, suppressed

anger, and risk of adverse events in patients with coronary artery

disease. Am J Cardiol. - 2010. 105:1555-1560.

46. Denollet J., Schiffer A.A., Spek V. A general propensity to

psychological distress affects cardiovascular outcomes: evidence from

research on the type D (distressed) personality profile. Circ Cardiovasc

Qual Outcomes. - 2010. 3:546-557.

47. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing

stroke and other vascular events in patients with vascular disease.

Cochrane Database Syst Rev. - 2007. -3:CD001820.

48. Di Francescomarino S., Sciartilli A., Di Valerio V., Di Baldassarre A.,

Gallina S. The effect of physical exercise on endothelial function.

Sports Med. - 2009. 39:797-812.

49. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, et al. Aspirin

and clopidogrel compared with clopidogrel alone after recent ischaemic

stroke or transient ischaemic attack in high-risk patients (MATCH):

randomised, double-blind, placebo-controlled trial. Lancet. - 2004. -

364:331-337.

50. Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in

relation to smoking: 40 years’ observations on male British doctors.

BMJ. - 1994. 309:901-911.

51. Drew B.S., Dixon A.F., Dixon J.B. Obesity management: update on

orlistat. Vasc Health Risk Manag. - 2007. 3:817-821.1701e Joint ESC

Guidelines.

52. Duckworth W., Abraira C, Moritz T., Reda D, Emanuele N., et al.

Glucose control and vascular complications in veterans with type 2

diabetes. N Engl J Med. - 2009. 360:129-139.

53. Dusseldorp E., van Elderen T., Maes S., Meulman J., Kraaij V. A meta-

analysis of psychoeduational programs for coronary heart disease

patients. Health Psychol. - 1999. 18:506-519.

54. Edwards R. The problem of tobacco smoking. BMJ. - 2004. - 328:217-

219.

55. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of

antihypertensive drugs: a network meta-analysis. Lancet. - 2007.

369:201-207.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

56. European Guidelines on cardiovascular disease prevention in clinical

practice (version 2012). European Heart Journal. - 2012. - 33, 1635-

1701 doi: 10.1093/eurheartj/ehs092

57. European Heart Network. European Cardiovascular Disease Statistics. -

2008 edition.

58. Food and Nutrition Board. Dietary Reference Intakes for Energy,

Carbohydrates, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino

Acids. Washington DC: National Academies Press. - 2002.

59. Fowkes FG, Murray GD, Butcher I, Heald CL, et al. Ankle brachial

index combined with Framingham Risk Score to predict cardiovascular

events and mortality: a meta-analysis. JAMA. - 2008. - 300:197-208.

60. Fletcher G.F., Balady G.J., Amsterdam E.A., Chaitman B., Eckel R.,

Fleg J., et al. Exercise standards for testing and training: a statement for

healthcareprofessionals from the American Heart Association.

Circulation. - 2001. 104:1694-1740.

61. Franklin B.A., Bonzheim K., Gordon S., Timmis GC. Safety of

medically supervised outpatient cardiac rehabilitation exercise therapy:

a 16 year follow-up. Chest. - 1998. 114:902-906.

62. Franklin B.A. Cardiovascular events associated with exercise. The

risk–protection paradox. J Cardiopulm Rehabil. - 2005. 25:189-195 /

quiz 196-187.

63. Fruchart JC, Sacks F, Hermans MP, Assmann G, et al. The Residual

Risk Reduction Initiative: a call to action to reduce residual vascular

risk in patients with dyslipidemia. Am J Cardiol. - 2008. - 102:p1K-

34K.

64. Garza C.A., Montori V.M., McConnell J.P., Somers V.K., Kullo I.J.,

Lopez-Jimenez F. Association between lipoprotein-associated

phospholipase A2 and cardiovascular disease: a systematic review.

Mayo Clin Proc. - 2007. - 82:159-165.

65. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J.,

Troxel A.B. Risk of myocardial infarction in patients with psoriasis.

JAMA. - 2006. 296:1735-1741.

66. Gibbons R.J., Abrams J., Chatterjee K., Daley J., Deedwania P.C.,

Douglas J.S., Ferguson T.B. Jr, et al. ACC/AHA 2002 guideline update

for the management of patients with chronic stable angina – summary

article: a report of the American College of Cardiology/American Heart

Association Task Force on Practice Guidelines (Committee on the

Management of Patients With Chronic Stable Angina). Circulation. -

2003. 107:149-158.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

67. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova

R., Zampelas A. European guidelines on cardiovascular disease

prevention in clinical practice: full text. Fourth Joint Task Force of the

European Society of Cardiology and other societies on cardiovascular

disease prevention in clinical practice (consti-tuted by representatives

of nine societies and by invited experts). Eur J Cardiovasc Prev

Rehabil. - 2007. 14 Suppl 2: S1-113.

68. Gurbel PA, Bliden KP, Butler K, Tantry US, et al. Randomized double-

blind assessment of the ONSET and OFFSET of the antiplatelet effects

of ticagrelor versus clopidogrel in patients with stable coronary artery

disease: the ONSET/OFFSET study. Circulation. - 2009. - 120:2577-

2585.

69. Hiatt W.R. Medical treatment of peripheral arterial disease and

claudication. N Engl J Med. - 2001. 344:1608-1621.

70. Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal

A, Coupland C. Antidepressants as risk factor for ischaemic heart

disease: case–control study in primary care. BMJ. - 2001. 323:666-669.

71. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The

Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom

Tolerance Questionnaire. Br J Addict. - 1991. 86:1119-1127.

72. He F.J., MacGregor G.A. Effect of modest salt reduction on blood

pressure: a meta-analysis of randomized trials. Implications for public

health. J Hum Hypertens. - 2002. 16:f1-770.

73. He FJ, MacGregor GA. Fortnightly review: beneficial effects of

potassium. BMJ. - 2001. 323:497-501.

74. He F.J., Nowson C.A., MacGregor G.A. Fruit and vegetable

consumption and stroke: meta-analysis of cohort studies. Lancet. -

2006. 367:320-326.

75. Heidenreich PA., Trogdon J.G., Khavjou O.A., Butler J., Dracup K.,

Ezekowitz M.D., Finkelstein E.A., Hong Y., Johnston S.C., Khera A., et

al. Forecasting the future of cardiovascular disease in the United States:

a policy statement from the American Heart Association. Circulation. -

2011. 123:933-944.

76. He J., Vupputuri S., Allen K., Prerost M.R., Hughes J., Whelton P.K.

Passive smoking and the risk of coronary heart disease - a meta-

analysis of epidemiologic studies. N Engl, J Med. - 1999. 340:920-926.

77. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R.,

Greenland P. Accumulated evidence on fish consumption and coronary

heart disease mortality: a meta-analysis of cohort studies. Circulation. -

2004. 109:2705-2711.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

78. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R.,

Goldbourt U., Greenland P. Fish consumption and incidence of stroke:

a meta-analysis of cohort studies. Stroke. - 2004. 35:1538-1542.

79. International Agency for Research on Cancer. Tobacco Control:

Reversal of Risk After Quitting Smoking. IARC Handbooks of Cancer

Prevention, Vol. 11. Lyon: IARC. - 2007.

80. Investigators TCT. Effects of clopidogrel in addition to aspirin in

patients with acute coronary syndromes without ST-segment elevation.

N Engl J Med. - 2001. - 345:494-502.

81. Jardine M.J., Ninomiya T., Perkovic V., Cass A., Turnbull F., Gallagher

M.P., Zoungas S., Lambers Heerspink H.J., Chalmers J., Zanchetti A.

Aspirin is beneficial in hypertensive patients with chronic kidney

disease: a post-hoc subgroup analysis of a randomized controlled trial. J

Am Coll Cardiol. - 2010. 56:956-965.

82. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V.,

Hester A., et al. Benazepril plus amlodipine or hydrochlorothiazide for

hypertension in high-risk patients. N Engl J Med. - 2008. 359:2417-

2428.

83. Jensen J, Blankenhorn DH, KornerupV. Coronary disease in familial

hypercholesterolemia. Circulation. - 1967. - 36:77-82.

84. Jousilahti P., Vartiainen E., Tuomilehto J., Puska P. Sex, age,

cardiovascular risk factors, and coronary heart disease: a prospective

follow-up study of 14 786 middle-aged men and women in Finland.

Circulation. - 1999. 99:1165-1172.

85. Katon W.J., Lin E.H., Von Korff M., Ciechanowski P., Ludman E.J.,

Young B., Peterson D., Rutter C.M., McGregor M., McCulloch D.

Collaborative care for patients with depression and chronic illnesses. N

Engl J Med. - 2010. 363:2611-2620.

86. Kaptoge S., White I.R., Thompson S.G., Wood A.M., et al. Associations

of plasma fibrinogen levels with established cardiovascular disease risk

factors, inflammatory markers, and other characteristics: individual

participant meta-analysis of 154,211 adults in 31 prospective studies:

the fibrinogen studies collaboration. Am J Epidemiol. - 2007. 166:867-

879.

87. Kodama S., Saito K., Tanaka S., Maki M., Yachi Y., Asumi M., et al.

Cardiorespiratory fitness as a quantitative predictor of all-cause

mortality and cardiovascular events in healthy men and women: a

meta-analysis. JAMA. - 2009. 301:2024-2035.

88. Lancaster T., Stead L. Physician advice for smoking cessation.

Cochrane Database Syst Rev. - 2004. 4: CD000165.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

89. La Rosa JC, Grundy SM, Waters DD, Shear C, et al. Intensive lipid

lowering with atorvastatin in patients with stable coronary disease. N

Engl J Med. - 2005. - 352:1425-1435.

90. Lawlor D.A., Ebrahim S., Davey Smith G. Sex matters: secular,

geographical trends in sex differences in coronary heart disease

mortality. BMJ. - 2001. 323:541-545

91. Law M.R., Morris J.K., Wald NJ. Environmental tobacco smoke

exposure and ischemic heart disease: an evaluation of the evidence.

BMJ. - 1997. 315:973-980.

92. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R.. Age-

specific relevance of usual blood pressure to vascular mortality: a

meta-analysis of individual data for one million adults in 61

prospective studies. Lancet. - 2002. 360:1903-1913.

93. Lightwood J.M., Glantz S.A. Declines in acute myocardial infarction

after smoke free laws and individual risk attributable to secondhand

smoke. Circulation. - 2009. 120:1373-1379.

94. Linden W., Phillips M.J., Leclerc J.. Psychological treatment of

cardiac patients: a meta-analysis. Eur Heart J. - 2007. 28:2972-2984.

95. Linke A., Erbs S., Hambrecht R.. Effects of exercise training upon

endothelial function in patients with cardiovascular disease. Front

Biosci. - 2008. 13:424-432.

96. Lippi G., Maffulli N. Biological influence of physical exercise on

hemostasis. Semin Thromb Hemost. - 2009. 35:269-276.

97. Liu M, Counsell C, Sandercock P. Anticoagulants for preventing

recurrence fol-lowing ischaemic stroke or transient ischaemic attack.

Cochrane Database Syst Rev. - 2000. - 2:CD00024

98. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., et al. Blood

pressure, stroke, and coronary heart disease. Part 1, Prolonged

differences in blood pressure: prospective observational studies

corrected for the regression dilution bias. Lancet. - 1990. 335:765-774.

99. Malik V.S., Popkin B.M., Bray G.A., Despres J.P., Hu F.B. Sugar -

sweetened beverages, obesity, type 2 diabetes mellitus, and

cardiovascular disease risk. Circulation. - 2010. 94:1356-1364.

100. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., et al.

2007 ESH-ESC Practice Guidelines for the Management of Arterial

Hypertension: ESH-ESC Task Force on the Management of Arterial

Hypertension. J Hypertens. - 2007. 25:1751-1762.

101. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, PerriD. Primary

prevention of cardiovascular mortality and events with statin

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

treatments: a network meta-analysis involving more than 65,000

patients. J Am Coll Cardiol. - 2008. - 52:1769-1781.

102. Mohr JP, Thompson JL, Lazar RM, Levin B, et al. A comparison of

warfarin and aspirin for the prevention of recurrent ischemic stroke. N

Engl J Med. - 2001. - 345:1444-1451.

103. Mollmann H., Liebetrau C., Nef H.M., Hamm C.W. The Swedish

paradox: or is there really no gender difference in acute coronary

syndromes? Eur Heart J. - 2011. 32:3070-3072.

104. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., et al.

Evidence-based guidelines for cardiovascular disease prevention in

women: 2007 update. Circulation. - 2007. 115:1481-1501.

105. Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human

health: evaluating the risks and the benefits. JAMA. - 2006. 296:1885-

1899.

106. Mozaffarian D., Katan M.B., Ascherio A., Stampfer M.J., Willett W.C.

Trans fatty acids and cardiovascular disease. N Engl J Med. - 2006.

354:1601-1613.

107. National Institute for Health and Clinical Excellence [Electronic

resource]: NICE Public Health Guidance 10. Smoking Cessation

Services in Primary Care, Pharmacies, Local Authorities and

Workplaces, Particularly for Manual Working Groups, Pregnant

Women and Hard to Reach Communities. - 2008. - Available at:

http://www.nice.org.uk/nicemedia/pdf/PH010guidance.pdf

(04.02.2014)

108. Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, et al. HMG

CoA reductase inhibitors (statins) for kidney transplant recipients.

Cochrane Database Syst Rev. - 2009. - 2: CD005019.

109. Neaton JD, Blackburn H, Jacobs D, Kuller L, et al. Serum cholesterol

level mortality findings for men screened in the Multiple Risk Factor

Intervention Trial. Multiple Risk Factor Intervention Trial Research

Group. Arch Intern Med - 1992.- 152:1490-1500.

110. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, et al.

Reductions in all-cause, cancer, and coronary mortality in statintreated

patients with heterozygous familial hypercholesterolaemia: a

prospective registry study. Eur Heart J. - 2008. - 29:2625-2633.

111. Neter J.E., Stam B.E., Kok F.J., Grobbee D.E., Geleijnse J.M.

Influence of weight reduction on blood pressure: a meta-analysis of

randomized controlled trials. Hypertension. - 2003. 42:878-884.

112. O’Connor C.M., Whellan D.J., Lee K.L., Keteyian S.J., Cooper L.S.,

.Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, et al.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

Efficacy and safety of exercise training in patients with chronic heart

failure: HF-ACTION randomized controlled trial. JAMA. - 2009.

301:1439-1450.

113. O’Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L.,

Wolfson S.K. Carotid-artery intima and media thickness as a risk

factor for myocardial infarction and stroke in older adults.

Cardiovascular Health Study Collaborative Research Group. N Engl J

Med. - 1999. 340:14-22.

114. Orth-Gomer K., Schneiderman N., Wang H.X., Walldin C., Blom M.,

Jernberg T. Stress reduction prolongs life in women with coronary

disease: the Stockholm Women’s Intervention Trial for Coronary Heart

Disease (SWITCHD). Circ Cardiovasc Qual Outcomes. - 2009. 2:25-32.

115. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., et al. Intensive

blood glucose control and vascular outcomes in patients with type 2

diabetes. N Engl J Med. - 2008. 358:2560-2572.

116. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot

L., et al. Effects of a fixed combination of perindopril and indapamide

on macrovascular and microvascular outcomes in patients with type 2

diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

Lancet. - 2007. 370:829-840.

117. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, et al. High-dose

atorvastatin vs usual-dose simvastatin for secondary prevention after

myocardialinfarction: the IDEAL study: a randomized controlled trial.

JAMA. - 2005. - 294:2437-2445.

118. Piepoli M.F., Corra U., Benzer W., Bjarnason-Wehrens B., Dendale P.,

et al. Secondary prevention through cardiac rehabilitation: from

knowledge to implementation. A position paper from the Cardiac

Rehabilitation Section of the European Association of Cardiovascular

Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. - 2010.

17:1-17.

119. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-

analysis of trials in patients with chronic heart failure (ExTraMATCH).

BMJ. - 2004. - 328:189.

120. Poirier P., Alpert M.A., Fleisher L.A., Thompson P.D., Sugerman H.J.,

et al. Cardiovascular evaluation and management of severely obese

patients undergoing surgery: a science advisory from the American

HeartAssociation. Circulation. - 2009. 120:86-95.

121. Poirier P., Cornier M.A., Mazzone T., Stiles S., Cummings S., et al.

Bariatric surgery and cardiovascular risk factors: a scientific statement

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

from the American Heart Association. Circulation. - 2011. 123:1683-

1701.

122. Poulter N.R., Wedel H., Dahlof B., Sever P.S., Beevers D.G., et al.

Role of blood pressure other variables in the differential

cardiovascular event rates noted in the Anglo-Scandinavian Cardiac

Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

Lancet. - 2005. 366:907-913.

123. Preis SR, Hwang SJ, Coady S, Pencina MJ, et al. Trends in all-cause

and cardiovascular disease mortality among women and men with and

without diabetes mellitus in the Framingham Heart Study, 1950 to

2005. Circulation. - 2009. - 119:1728-1735

124. Prescott E., Hippe M., Schnohr P., Hein H.O., Vestbo J. Smoking and

risk of myocardial infarction in women and men: longitudinal

population study. BMJ. - 1998. 316:1043-1047.

125. Prescott E., Scharling H., Osler M., Schnohr P.. Importance of light

smoking and inhalation habits on risk of myocardial infarction and all

cause mortality. A 22 year follow up of 12 149 men and women in The

Copenhagen City Heart Study. J Epidemiol Community Health. -

2002. 56:702-706.

126. Raupach T., Schafer K., Konstantinides S., Andreas S.. Secondhand

smoke as an acute threat for the cardiovascular system: a change in

paradigm. Eur Heart J. - 2006. 27:386-392.

127. Ray KK, Cannon CP, McCabe CH, Cairns R, et al. Early and late

benefits of high-dose atorvastatin in patients with acute coronary

syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll

Cardiol. - 2005. -46:1405-1410.

128. Rayner M., Allender S., Scarborough P. Cardiovascular disease in

Europe. Eur J Cardiovasc Prev Rehabil. - 2009. - 16 Suppl 2: S43-S47.

129. Rees K., Bennett P., West R., Davey S.G., Ebrahim S. Psychological

interventions for coronary heart disease. Cochrane Database Syst Rev.

- 2004. 2: CD002902.

130. Richardson C.R., Kriska A.M., Lantz P.M., Hayward R.A. Physical

activity and mortalityacross cardiovascular disease risk groups. Med

Sci Sports Exerc. - 2004. 36:1923-1929.

131. Rigotti N.A., Pipe A.L., Benowitz N.L., Arteaga C., Garza D., Tonstad

S. Efficacy and safety of varenicline for smoking cessation in patients

with cardiovascular disease: a randomized trial. Circulation. - 2010.

121:221-229.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

132. Roest A.M., Martens E.J., de Jonge P., Denollet J. Anxiety and risk of

incident coronary heart disease: a meta-analysis. J Am Coll Cardiol,

2010. - 56:38-46.

133. Roest A.M., Martens E.J., Denollet J., de Jonge P. Prognostic

association of anxiety post myocardial infarction with mortality and

new cardiac events: a meta-analysis. Psychosom Med. - 2010. 72:563-

569.

134. Rose G. Sick individuals and sick populations. Int J Epidemiol. - 1985.

14:32-38.

135. Rollman B.L., Belnap B.H., LeMenager M.S., Mazumdar S., Houck

P.R., et al. Telephone-delivered collaborative care for treating post-

CABG depression: a randomized controlled trial. JAMA, - 2009. -

302:2095-2103.

136. Romero-Corral A., Montori V.M., Somers V.K., Korinek J., Thomas

R.J., et al. Association of bodyweight with total mortality and with

cardiovascular events in coronary artery disease: a systematic review

of cohort studies. Lancet. - 2006. 368:666-678.

137. Rozanski A., Blumenthal J.A., Davidson K.W., Saab P.G., Kubzansky

L. The epidemiology, pathophysiology, and management of

psychosocial risk factors in cardiac practice: the emerging field of

behavioral cardiology. J Am Coll Cardiol. - 2005. 45:637-651.

138. Rubak S., Sandbaek A., Lauritzen T., Christensen B. Motivational

interviewing: a systematic review and meta-analysis. Br J Gen Pract. -

2005. 55:305-312.

139. Ruilope L.M., Salvetti A., Jamerson K., Hansson L., Warnold I., Wedel

H., Zanchetti A. Renal function and intensive lowering of blood

pressure in hypertensive participants of the hypertension optimal

treatment (HOT) study. J Am Soc Nephrol, - 2001. - 12:218-225.

140. Sacco RL, Diener HC, Yusuf S, Cotton D, et al. Aspirin and extended-

release ipyridamole versus clopidogrel for recurrent stroke. N Engl J

Med. - 2008. - 359:1238-1251.

141. Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., et al.

Effects on blood pressure of reduced dietary sodium and the Dietary

Approaches to Stop Hypertension (DASH) diet. DASH–Sodium

Collaborative Research Group. N Engl J Med. - 2001. 344:3-10.

142. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal

outcomes: a meta-analysis. J Am Soc Nephrol. - 2006. - 17:2006-2016.

143. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, et al. Triglycerides

and the risk of coronary heart disease: 10,158 incident cases among

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

262,525 participants in 29 Western prospective studies. Circulation. -

2007. - 115:450-458.

144. Scheinowitz M., Harpaz D. Safety of cardiac rehabilitation in a

medically supervised, community-based program. Cardiology. - 2005.

103:113-117.

145. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease:

effects on the cardiovascular system. Circulation, - 2007. - 116:85-97.

146. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P,et al. Effects of

atorvastatin on early recurrent ischemic events in acute coronary

syndromes: the MIRACL study: a randomized controlled trial. JAMA.

- 2001. - 285:1711-1718.

147. Sehestedt T., Jeppesen J., Hansen T.W., Wachtell K., Ibsen H., et al.

Risk prediction is improved by adding markers of subclinical organ

damage to SCORE. Eur Heart J. - 2010. 31:883-891.

148. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., et al.

Effect of lowering LDL cholesterol substantially below currently

recommended levels in patients with coronary heart disease and

diabetes: the Treating to New Targets (TNT) study. Diabetes Care. -

2006. 29:1220-1226.

149. SIGN (Scottish Intercollegiate Guidelines Network) [Electronic

resource]: Risk Estimation and the Prevention of Cardiovascular

Disease. A National Clinical Guideline. - 2007. Report No. 97.

Availabe at: http://www.sign.ac.uk/pdf/sign97.pdf (12.02.2014).

150. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol

concentration, mortality. The Whitehall Study. JAMA. - 1992. -

267:70-76.

151. Steenland K. Risk assessment for heart disease and workplace ETS

exposure among nonsmokers. Environ Health Perspect. - 1999. 107 //

Suppl 6:859-863.

152. Stead L.F., Lancaster T. Group behaviour therapy programmes for

smoking cessation. Cochrane Database Syst Rev. - 2005. 2:CD001007.

153. Stringhini S., Sabia S., Shipley M., Brunner E., Nabi H., Kivimaki M.,

Singh-Manoux A. Association of socioeconomic position with health

behaviors and mortality. JAMA. - 2010. 303:1159-1166.

154. Talbot L.A., Morrell C.H., Fleg J.L., Metter E.J. Changes in leisure

time physical activity and risk of all-cause mortality in men and

women: the Baltimore Longitudinal Study of Aging. Prev Med. - 2007.

45:169-176.

155. Taylor R.S., Brown A., Ebrahim S., Jolliffe J., Noorani H., et al.

Exercise-based rehabilitation for patients with coronary heart disease:

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

systematic review and meta-analysis of randomized controlled trials.

Am J Med. - 2004. 116:682-692.

156. Theorell T., Emdad R., Arnetz B., Weingarten A.M. Employee effects

of an educational program for managers at an insurance company.

Psychosom Med. - 2001. 63:724-733.

157. Thompson P.D., Franklin B.A., Balady G.J., Blair S.N., Corrado D., et

al. Exercise and acute cardiovascular events placing the risks into

perspective: a scientific statement from the AmericanHeart Association

Council on Nutrition, Physical Activity, and Metabolism and the

Council on Clinical Cardiology. Circulation. - 2007. 115:2358-2368.

158. Thun M.J., Myers D.G., Day-Lally C., Namboodin M.M., Calle E.E.,

et al. Age and the exposure-response relationships between cigarette

smoking and premature death in Cancer Prevention Study II. Changes

in Cigarette-Related Disease Risks and Their Implications for

Prevention and Control. Smoking and Tobacco Control Monograph

No. 8. Bethesda, MD: US Department of Health and Human Services,

Public Health Service, National Institutes of Health, National Cancer

Institute. - 1997. 383-413.

159. Tipton C.M. ACSM’s Advanced Exercise Physiology. Baltimore, MD:

Lippincott Williams & Wilkins. - 2006.

160. Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., et al. Effects

of different blood pressure-lowering regimens on major cardiovascular

events in individuals with and without diabetes mellitus: results of

prospectively designed overviews of randomized trials. Arch Intern

Med. - 2005. 165:1410-1419.

161. UK Prospective Diabetes Study Group. Effect of intensive blood-

glucose control with metformin on complications in overweight

patients with type 2 diabetes (UKPDS 34). Lancet. - 1998. 352:854-865.

162. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-

glucose control with sulphonylureas or insulin compared with

conventional treatment and risk of complications in patients with type

2 diabetes (UKPDS 33). Lancet. - 1998. 352:837-853.

163. US Department of Health and Human Services [Electronic resource]:

Physical Activity Guidelines Advisory Committee Report. 2008. -

Availabe

at:

http://www.health.gov/PAguidelines/

Report/

pdf/CommitteeReport.pdf. 312 (12.02.2014). // Richardson CR, Kriska

AM, Lantz PM, Hayward RA. Physical activity and mortality across

cardiovascular disease risk groups. Med Sci Sports Exerc. - 2004.

36:1923-1929.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

164. US Department of Health and Human Services [Electronic resource].

2008 Physical Activity Guidelines for Americans. - 2008. Availabe at:

http://www.health.gov/paguidelines/pdf/ paguide.pdf (12.02.2014).

165. Vogt M.T., Cauley J.A., Newman A.B., Kuller L.H., Hulley S.B.

Decreased ankle/arm blood pressure index and mortality in elderly

women. JAMA 1993; 270:465–469.

166. Wamala S.P., Mittleman M.A., Schenck-Gustafsson K., Orth-Gomer

K. Potential explanations for the educational gradient in coronary heart

disease: a population-based case-control study of Swedish women. Am

J Public Health. - 1999. 89:315-321.

167. Wald D.S., Law M., Morris J.K., Bestwick J.P., Wald N.J.

Combination therapy versus monotherapy in reducing blood pressure:

meta-analysis on 11,000 participants from 42 trials. Am J Med. - 2009.

122:290-300.

168. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., et

al. Ticagrelor versus clopidogrel in patients with acute coronary

syndromes. N Engl J Med. - 2009.361:1045-1057.

169. Warren T.Y., Barry V., Hooker S.P., Sui X., Church T.S., Blair SN.

Sedentary behaviors increase risk of cardiovascular disease mortality

in men. Med Sci Sports Exerc. - 2010. 42:879-885.

170. Wattigney W.A., Mensah G.A., Croft J.B. Increasing trends in

hospitalization for atrial fibrillation in the United States, 1985 through

1999: implications for primary prevention. Circulation. - 2003.

108:711-716.

171. Weickert M.O., Pfeiffer A.F. Metabolic effects of dietary fiber

consumption and prevention of diabetes. J Nutr. - 2008. 138:439-442.

172. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., et al.

Body-mass index and cause-specific mortalityin 900 000 adults:

collaborative analyses of 57 prospective studies. Lancet. - 2009.

373:1083-1096.

173. Whooley M.A., de Jonge P., Vittinghoff E., Otte C., Moos R., et al.

Depressive symptoms, health behaviors, and risk of cardiovascular

events in patients with coronary heart disease. JAMA. - 2008.

300:2379-2388.

174. WHO Study Group on Tobacco Product Regulation TobReg.

Waterpipe Tobacco Smoking: Health Effects, Research Needs and

Recommended Actions by Regulators. - 2005.

175. Williams P.T. Physical fitness and activity as separate heart disease

risk factors: a meta-analysis. Med Sci Sports Exerc. - 2001. 33:754-761.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

yy

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

176. Williams R.R., Hunt S.C., Heiss G., Province M.A., Bensen J.T., et al.

Usefulness of cardiovascular family history data for population-based

preventive medicine and medical research (the Health Family Tree

Study and the NHLBI Family Heart Study). Am J Cardiol. - 2001.

87:129-135.

177. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., et

al. Prasugrel versus clopidogrel in patients with acute coronary

syndromes. N Engl J Med. - 2007. 357:2001-2015.

178. World Health Organization. Joint WHO/FAO Expert Consultation on

Diet, Nutrition and the Prevention of Chronic Diseases. - 2002. Report

No. 916.

179. World Health Organization. Obesity: Preventing and Managing the

Global Epidemic.Report of a WHO Consultation. World Health

Organization Technical Report Series, Report No 894. - 1998.

180. Zanchetti A., Hansson L., Dahlof B., Julius S., Menard J., et al. Benefit

and harm of low-dose aspirin in well-treated hypertensives at different

baseline cardiovascular risk. J Hypertens. - 2002. 20:2301-2307.

181. Zheng W., McLerran D.F., Rolland B., Zhang X., Inoue M., et al.

Association between body-mass index and risk of death in more than 1

million Asians.N Engl J Med. - 2011. 364:719-729.

Klinik protokol Az

ərbaycan Respublikas

ı S

əhiyy

ə Nazirliyinin

İctimai S

əhi

ə v

İslahatlar M

ərk

əzind

ə haz

ırlanm

ış

dı

r.

Yüklə 0,77 Mb.

Dostları ilə paylaş:

1 ... 57 58 59 60 61 62 63 64 65